Basilea's Ceftobiprole Dubbed Qualified Infectious Disease Product
This article was originally published in Scrip
Executive Summary
Basilea Pharmaceutica's ceftobiprole was designated by the FDA as a qualified infectious disease product – a status under which the drug is eligible for an additional five years of market exclusivity if approved for the indications.
You may also be interested in...
Keeping Track: So. Much. News.
The latest drug development news and highlights from our US FDA Performance Tracker.
Basilea's Business Strategy Emboldened By $500m Pfizer Deal
Swiss company Basilea has attracted Pfizer as a European partner for its antifungal Cresimba and plans to strengthen its development pipeline with licensed-in products and further collaborations.
Moderna's Valera Takes mRNA Approach To Combat Zika
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.